We are live on ! Find out more
AGRX

Agile Therapeutics
AGRX

Delisted

AGRX was delisted on the 25th of March, 2024.

Back to rankings

49 hedge funds and large institutions have $30.5M invested in Agile Therapeutics in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

656% more call options, than puts

Call options by funds: $363K | Put options by funds: $48K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

23% less funds holding

Funds holding: 64 → 49 (-15)

33% less capital invested

Capital invested by funds: $45.7M → $30.5M (-$15.2M)

47% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 19

94% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 16

Holders
49
Holders Change
-15
Holders Change %
-23.44%
% of All Funds
0.86%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
10
Reduced
19
Closed
16
Calls
$363K
Puts
$48K
Net Calls
+$315K
Net Calls Change
-$118K

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$258K
2
GCP
GSA Capital Partners
United Kingdom
+$242K
3
BlackRock
BlackRock
New York
+$183K
4
Northern Trust
Northern Trust
Illinois
+$79.2K
5
SGI
Summit Global Investments
Utah
+$18.1K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$905K
2
Millennium Management
Millennium Management
New York
-$638K
3
TEE
Tibra Equities Europe
United Kingdom
-$321K
4
Goldman Sachs
Goldman Sachs
New York
-$305K
5
Morgan Stanley
Morgan Stanley
New York
-$283K
Name Holding Trade Value Shares
Change 		Change in
Stake
HSA
26
HBK Sorce Advisory
Pennsylvania
$34K – – –
Citadel Advisors
27
Citadel Advisors
Florida
$32K -$111K -49 -75%
CS
28
Candriam SCA
Luxembourg
$28K – – –
Simplex Trading
29
Simplex Trading
Illinois
$26K – – –
VF
30
Virtu Financial
New York
$26K +$15.8K +7 +100%
LPL Financial
31
LPL Financial
California
$25K – – –
RJA
32
Raymond James & Associates
Florida
$25K – – –
Principal Financial Group
33
Principal Financial Group
Iowa
$17K -$2.26K -1 -10%
KM
34
Kalos Management
Georgia
$15K -$2.26K -1 -10%
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
$11K – – –
Victory Capital Management
36
Victory Capital Management
Texas
$11K +$2.26K +1 +20%
Barclays
37
Barclays
United Kingdom
$11K +$4.53K +2 +50%
ECM
38
ExodusPoint Capital Management
New York
$10K -$81.5K -36 -88%
CWM
39
Centric Wealth Management
Illinois
$10K – – –
Creative Planning
40
Creative Planning
Kansas
$10K – – –
PFM
41
Parsec Financial Management
North Carolina
$8K +$13.6K +6 New
Citigroup
42
Citigroup
New York
$7K – – –
Bank of America
43
Bank of America
North Carolina
$6K -$2.26K -1 -20%
FCMT
44
Founders Capital Management (Texas)
Texas
$5K -$4.53K -2 -40%
IA
45
IFP Advisors
Florida
$5K – – –
JP Morgan Chase
46
JP Morgan Chase
New York
$4K -$147K -65 -97%
APWA
47
Atlas Private Wealth Advisors
New Jersey
$2K – – –
Wells Fargo
48
Wells Fargo
California
$2K – – –
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$1.85K – – –
TEE
50
Tibra Equities Europe
United Kingdom
– -$321K -121 Closed
1
2
3

AGRX Hedge Fund Activity: Q3 2021 in Review

49 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q3 2021, worth a combined $30.5M — down 33% from $45.7M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AGRX and 1 opened new positions — a net loss of 15 holders — while 19 trimmed existing stakes and 10 added.

The largest buyer was D.E. Shaw & Co, adding an estimated $258K. The largest seller was Renaissance Technologies, cutting an estimated $905K.

  • 49 institutional investors held Agile Therapeutics (AGRX) as of Q3 2021, down from 64 in Q2 2021.
  • Funds reported $30.5M of Agile Therapeutics stock for Q3 2021, down 33% quarter-over-quarter.
  • 1 fund opened new Agile Therapeutics positions in Q3 2021 and 16 closed out, a net change of -15 holders.
  • The largest Agile Therapeutics buyer in Q3 2021 was D.E. Shaw & Co, an estimated $258K added.
  • The largest Agile Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $905K sold.

Based on aggregated 13F filings for Q3 2021.